Research programme: therapeutic antibodies - Pfizer/BioWa/Lonza

Drug Profile

Research programme: therapeutic antibodies - Pfizer/BioWa/Lonza

Latest Information Update: 02 Aug 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 30 Jul 2013 BioWa and Lonza enter into research and commercialisation agreements with Pfizer for use of their technology for therapeutic antibody research and development at Pfizer
  • 30 Jul 2013 Early research in Undefined indication in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top